Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 4;10:7488. doi: 10.1038/s41598-020-63294-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of VE-822 as a single agent and in combination with gemcitabine on cell cycle and apoptosis in soft-tissue sarcoma cells. (A) Cell-cycle profile after 48 h of treatment with gemcitabine and/or VE-822 analyzed by PI incorporation and flow cytometry in the IB111 cell line. (B) Effect of gemcitabine and VE-822 combination on cell cycle progression in 6 STS cell lines: IB111, IB112, IB115, IB128, 93T449 and IB136. Cell-cycle distribution was calculated from the flow cytogram. (C) Annexin V FITC-A vs propidium iodide-A plots from the gated cells show the populations corresponding to viable and non-apoptotic (Annexin V−PI−), early (Annexin V + PI−), and late (Annexin V + PI+) apoptotic cells in the IB111 cell line. (D) Quantification of apoptotic cells after 72 h of treatment with VE-822 or Gemcitabine alone or a combination of the two drugs.